• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Biogen to acquire rare disease drugmaker Reata for $7.3B

cafead

Administrator
Staff member
  • cafead   Jul 28, 2023 at 11:52: AM
via The deal is a major bet by Biogen on the biotech and its newly approved drug for the rare genetic condition Friedreich’s Ataxia.

article source